Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


First Commercial Sales Achieved for Cxbladder in the USA

18 October 2013

First Commercial Sales Achieved for Pacific Edge’s Cxbladder in the USA

Cancer diagnostic specialist Pacific Edge (NZX:PEB) is delighted to announce that it has completed the first commercial sales of Cxbladder tests signalling the start of the commercial revenue for the company in the US. The tests were ordered by US based clinicians and processed in Pacific Edge USA (PEDUSA)’s custom laboratory in Hershey Pennsylvania.

Earlier this week Pacific Edge finalised an agreement1 with national preferred provider network, FedMed to enable 40 million Americans to have access to Cxbladder. Negotiations are also underway with other national provider networks to broaden the access to Cxbladder.

The commercial relationship with FedMed provides FedMed’s contracted insurance carriers, third party administrators, health and welfare funds, and self-insured health plans with access to Cxbladder. More than 40 million Americans have access to FedMed’s National Provider Network of over 550,000 physicians, 4,000 hospitals and 60,000 ancillary care providers nationwide.

The commercial rollout of Cxbladder in July followed certification of the purpose built and equipped molecular diagnostic, CLIA approved, laboratory in Hershey.

PEDUSA Chief Executive Officer Jackie Walker says “the laboratory, custom built for high throughput testing with the design capacity to process up to 4000 tests per week, is achieving the design expectations and the processing of patient samples is exceeding the prompt turnaround times expected by clinicians delivering on our brand promise”.

“Our US sales and marketing team have segmented the market to focus the sales force and resources on the clinicians who are treating the largest number of bladder cancer patients. This includes large commercial payers and the Centre of Medicare and Medicaid Services, (CMS), which provides healthcare for 100 million people or nearly a third of the American population. Other key sales targets include the Veterans Administration (VA), Health Maintenance Organisations (HMOs) and Large Urology Groups (LUGS) who are the point of contact for many patients presenting with haematuria (blood in the urine) which is an early indicator of possible bladder cancer,” says Jackie Walker.

More than one million Americans will have undergone medical investigation this year for possible bladder cancer at an estimated cost of $US1 billion. Bladder cancer is one of the most expensive cancers to treat with regular testing required over a five year period after the initial diagnosis. With the very high recurrence of this disease some patients are receiving expensive monitoring for the rest of their life giving rise to bladder cancer having the highest total medical costs of any cancer from detection to death, approaching $US220,000 per patient in the USA.

The US team is building on the experience gained with User Programs and studies undertaken with leading urologists in a number of countries to improve the understanding by clinicians of the effectiveness of Cxbladder and its ability to detect urolthelial carcinomas.

Pacific Edge Chief Executive Officer David Darling says the building blocks are in place to achieve commercial success in the US, the world’s largest health market. “We are now starting to work with leading patient advocacy groups create patient awareness to compliment the growing uptake by clinicians.

“With Cxbladder available to patients in New Zealand, Australia and now the US, patients who have cancer quickly become very aware of the long road of care management that is likely to be needed in their disease management and the extensive and invasive nature of the disease monitoring process. As they gain an understanding of Cxbladder and its non-invasive urine sample process they are becoming strong proponents of our test,” David Darling says.

“We are confident that the outstanding performance of Cxbladder as a highly efficient cancer detection test and its patient friendly sample collection technology will be endorsed by clinicians and patients in the US and other markets we target.”

Evidence of that is already being demonstrated in New Zealand, where Pacific Edge is negotiating with health boards (DHBs) to follow the lead of the signing of MidCentral DHB to use Cxbladder as a cost effective means of triaging patients presenting with micro haematuria. Cxbladder is being made available to clinicians and their patients in Australia by Healthscope, the country’s largest provider of private healthcare. Soon it will made available by Oryzon to residents of Spain, the country with the highest incidence of bladder cancer in the world.


© Scoop Media

Business Headlines | Sci-Tech Headlines


Federated Farmers: Applauds UK-Australia Free Trade Deal

News that Australia and the UK have signed a free trade agreement is a promising step forward in the fight against tariffs and protectionism, Federated Farmers says.
"It reinforces the international rules-based trading framework and is important for rural producers and global consumers," Feds President Andrew Hoggard says... More>>

REINZ May Data: House Price Rises Continue; Auckland Hits New Record Median Price Again

Median prices for residential property across New Zealand increased by 32.3% from $620,000 in May 2020 to $820,000 in May 2021, according to the latest data from the Real Estate Institute of New Zealand (REINZ), source of the most complete and accurate real estate data in New Zealand... More>>

Energy Resources Aotearoa: Doubling Of Coal Use Shows Need For Local Natural Gas

New figures showing a near doubling of coal-fired electricity generation highlight New Zealand’s energy shortage and the need for natural gas as a lower carbon alternative, according to Energy Resources Aotearoa... More>>

Reserve Bank: Debt Serviceability Restrictions Added To Policy Toolkit

The Reserve Bank – Te Pūtea Matua and the Minister of Finance have agreed to update their shared Memorandum of Understanding (MoU) on macro-prudential policy and add debt serviceability restrictions to the list of potential tools available... More>>

Auction: 1.4 Million In Rare Vintage Watches, Gems, Jewels & Diamonds Go Under The Hammer At Webb’s

An auction event showcasing over 1.4 Million dollars in rare jewels, gems, diamonds and vintage watches is due to take place this Sunday by Auckland based auction house Webb’s... More>>

Catalist: NZ’s New SME Stock Exchange, Gets Licence To Go Public

New Zealand has a new stock exchange – designed specifically for small and medium-sized businesses (SMEs) to raise up to $20 million a year from the public.
Called Catalist, the exchange has already been successfully working the private investment sector.... More>>